The lower rating came from HSBC, which cited too much optimism around its new weight-loss pill, and the strength of Novo ...

HSBC analyst warns of a downside in Eli Lilly stock to $700. Rajesh Kumar cited 'valuation' as his number 1 concern.

Todd Engel claims Ozempic caused his blindness. Lawsuit says Novo Nordisk failed to warn of rare vision risks.

Their own mini-boom of recent years has been largely fueled by one firm, Ozempic maker Novo Nordisk A/S, whose diabetes and ...

President Donald Trump is under pressure to decide how widely available anti-obesity drugs should be and whether Medicare ...

Eli Lilly announced clinical trial results this week for a daily pill to treat obesity and diabetes. Its name is absolutely ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

An elderly American man has become completely blind after he was prescribed to take Ozempic to manage his type 2 diabetes.

A man who took Ozempic and then became legally blind is suing the manufacturer, arguing it should have warned patients that ...

Ozempic and similar weight loss drugs are currently at the center of multidistrict litigation over claims that the drugs ...

The court ruled in favor of Novo Nordisk and the FDA, rejecting a compounding pharmacy group's attempt to stop the FDA's ...

Novo Nordisk scored a legal win against compounders of its blockbuster GLP-1 drugs. But it may not end the copycats.